Restless legs syndrome following the use of ziprasidone: a case report  

作　　者：Cuizhen Zhu Ran Bi Yuliang Hu Hui Zhou Daomin Zhu Brian Isaacson Qingwei Li Yezhe Lin 

机构地区：[1]Department of Sleeping Disorder,Anhui Mental Health Center,Hefei,Anhui,China [2]Department of Psychiatry,Shanghai Mental Health Center,Shanghai Jiao Tong University,School of Medicine,Shanghai,China [3]School of Public Health,Schulich School of Medicine and Dentistry,London,Ontario,Canada [4]Departm ent of Psychiatry and Psychology,Mayo Clinic School of Graduate Medical Education,Rochester,Minnesota,USA [5]Shanghai Mental Health Center,Shanghai,China [6]Psychiatry Department,AtlantiCare Regional Medical Center,Atlantic City,New Jersey,USA [7]Department of Psychiatry,University of Rochester Medical Center,Rochester,New York,USA

出　　处：《General Psychiatry》2020年第2期111-113,共3页综合精神医学（英文）

基　　金：This case report was funded by Psychosomatic Medicine Project of Key Developing Disciplines of Shanghai Municipal Health Commission(2019ZB0202)in China.

摘　　要：Restless legs syndrome(RLS)is a common sleep-related movement disorder characterised by an uncomfortable urge to move the legs that occurs during periods of inactivity.Although there have been many case reports on antipsychotic-induced RLS,ziprasidone has never been reported as a cause of RLS.We present a case of a female patient with schizophrenia who presented with symptoms of RLS following the administration of high doses of ziprasidone added to quetiapine and valproate.The patient’s symptoms of RLS occurred following the administration and titration of ziprasidone to 160 mg,and were relieved upon reducing the dose to 120 mg/day.Other potential causative medications and differential diagnoses that could have caused similar symptoms were excluded.Clinicians should be aware of the potential for ziprasidone-induced RLS.Dopamine and serotonin interaction could be the mechanism underlying ziprasidone-induced RLS.

关 键 词：doses DOPAMINE MEDICATION 

分 类 号：R741[医药卫生—神经病学与精神病学]